{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:31:28Z","timestamp":1790454688100,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.semcancer.2011.09.008","type":"journal-article","created":{"date-parts":[[2011,9,18]],"date-time":"2011-09-18T17:46:29Z","timestamp":1316367989000},"page":"335-346","source":"Crossref","is-referenced-by-count":38,"title":["New molecular targets in mantle cell lymphoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Samir","family":"Parekh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Weniger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2011.09.008_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","article-title":"Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma","volume":"132","author":"Rinaldi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13402-011-0019-7","article-title":"Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling","volume":"34","author":"Pighi","year":"2011","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0020","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1182\/blood-2005-10-4042","article-title":"Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas","volume":"107","author":"Fu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0025","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1182\/blood-2008-10-183467","article-title":"BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB\/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells","volume":"113","author":"Fu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT WNT and TGFbeta signalling pathways","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0035","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.humpath.2007.05.009","article-title":"Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma","volume":"38","author":"Chim","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0040","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/hmg\/ddh195","article-title":"Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes","volume":"13","author":"de Leeuw","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0045","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2009-12-257485","article-title":"Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma","volume":"116","author":"Leshchenko","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0060","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2853","article-title":"The tipping points in the initiation of B cell signalling: how small changes make big differences","volume":"10","author":"Pierce","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0065","first-page":"964","article-title":"The Btk inhibitor, PCI-32765 induces durable responses with minimal toxicity in patients with relapsed\/refractory B-cell malignancies: results from a phase I study","volume":"116","author":"Fowler","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl.; abstr 8012","key":"10.1016\/j.semcancer.2011.09.008_bib0070","article-title":"Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma","volume":"29","author":"Raje","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tibs.2007.12.002","article-title":"Mining for JAK\u2013STAT mutations in cancer","volume":"33","author":"Constantinescu","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0080","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5858\/2005-129-990-ASOTSP","article-title":"Activation status of the JAK\/STAT3 pathway in mantle cell lymphoma","volume":"129","author":"Yared","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0085","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2009.019745","article-title":"Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma","volume":"95","author":"Baran-Marszak","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0090","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-10-0238","article-title":"Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications","volume":"9","author":"Pham","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0095","first-page":"2830","article-title":"Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"116","author":"Younes","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0105","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0110","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1073\/pnas.0510772103","article-title":"Oncogenic transformation induced by the p110beta -gamma, and -delta isoforms of class I phosphoinositide 3-kinase","volume":"103","author":"Kang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0115","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0120","first-page":"1777","article-title":"Clinical safety and activity in a Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"116","author":"Kahl","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0125","first-page":"1783","article-title":"Phase I study of novel prodrug dual PI3K\/mTOR inhibitor SF1126 in B-cell malignancies","volume":"116","author":"Garlich","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0130","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-009-0016-4","article-title":"Perifosine: update on a novel Akt inhibitor","volume":"11","author":"Gills","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0140","first-page":"1842","article-title":"Pre-clinical and interim results of a Phase II trial of perifosine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"116","author":"Friedman","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0145","first-page":"436","article-title":"Genomic and pathway connectivity analyses identify novel strategies to overcome mTOR inhibitor resistance in DLBCL","volume":"116","author":"Petrich","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0150","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1517\/13543784.2010.520701","article-title":"Akt inhibitors in clinical development for the treatment of cancer","volume":"19","author":"Pal","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0160","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0170","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0175","first-page":"3963","article-title":"PILLAR-1: preliminary results of a Phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib","volume":"116","author":"O\u2019Connor","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0180","first-page":"2803","article-title":"A multi-center Phase II study (SAKK 36\/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"116","author":"Renner","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0185","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0190","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0195","first-page":"3242","article-title":"Targeted inhibition of mTORC1 and mTORC2 by the active-site mTOR inhibitors, PP-242 and OSI-027, has cytotoxic effects in T-cell acute lymphoblastic leukemia","volume":"116","author":"Evangelisti","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0200","first-page":"778","article-title":"Targeting mTORC1\/2 by a mTOR kinase inhibitor (PP242) induces apoptosis in AML cells under conditions mimicking bone marrow microenvironment","volume":"116","author":"Zeng","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0205","first-page":"772","article-title":"Dual inhibition of mTORC1\/mTORC2 induces apoptosis of mantle cell lymphoma by preventing rictor mediated AKTS473 phosphorylation by potentiating AKT2-PHLPP1 association","volume":"116","author":"Gupta","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0210","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0215","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0220","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0225","series-title":"Mantle cell lymphoma consortium meeting proceedings","article-title":"Mechanism-based targeting of CDK4\/CDK6 in mantle cell lymphoma","author":"Chen-Kiang","year":"2011"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0230","series-title":"Mantle cell lymphoma consortium meeting proceedings","article-title":"Pilot study of the cdk4\/6 Inhibitor PD0332991 in mantle cell lymphoma: final results","author":"Shapiro","year":"2011"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0235","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0240","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0245","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.leukres.2010.12.010","article-title":"Cyclin-dependent kinase inhibitor P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription","volume":"35","author":"Manohar","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0250","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/onc.2009.510","article-title":"AT7519, a novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition","volume":"29","author":"Santo","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0255","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1535-7163.MCT-09-1071","article-title":"AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples","volume":"9","author":"Squires","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"Pt 21","key":"10.1016\/j.semcancer.2011.09.008_bib0260","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1242\/jcs.112.21.3591","article-title":"Aurora\/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases","volume":"112","author":"Giet","year":"1999","journal-title":"J Cell Sci"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0265","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bcp.2011.01.017","article-title":"Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma","volume":"81","author":"Qi","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0270","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1357-2725(99)00028-X","article-title":"ATM: the product of the gene mutated in ataxia-telangiectasia","volume":"31","author":"Lavin","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0275","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/(SICI)1098-2264(199804)21:4<298::AID-GCC3>3.0.CO;2-U","article-title":"Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma","volume":"21","author":"Monni","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0280","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2010.08.015","article-title":"MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma","volume":"299","author":"Jin","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0285","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","article-title":"MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma","volume":"15","author":"Tabe","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0290","first-page":"657","volume":"116","author":"Andreeff","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0295","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-10-0526","article-title":"Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer","volume":"16","author":"Annunziata","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0300","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0305","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0310","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","article-title":"BCL-2 family: regulators of cell death","volume":"16","author":"Chao","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0320","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0325","first-page":"770","article-title":"Rational for the use of a targeted-therapy using ABT-737 in mantle-cell lymphoma","volume":"116","author":"Touzeau","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0330","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","article-title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1","volume":"115","author":"Yecies","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0335","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0340","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","article-title":"Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia","volume":"113","author":"O\u2019Brien","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0345","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2008-02-138560","article-title":"AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance","volume":"113","author":"Balakrishnan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0350","doi-asserted-by":"crossref","unstructured":"Herishanu Y, Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, Bern S, et al. Activation of CD44, a receptor for extracellular matrix components, protects CLL cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 2011;52:1758\u201369.","DOI":"10.3109\/10428194.2011.569962"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0355","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-10-3367","article-title":"Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma","volume":"17","author":"Weniger","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0360","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0365","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2006.06247.x","article-title":"The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt Bid and activating caspase 9","volume":"135","author":"Georgakis","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0370","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2174\/156802609789895728","article-title":"Update on Hsp90 inhibitors in clinical trial","volume":"9","author":"Kim","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0375","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Roue","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0380","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2010.08265.x","article-title":"Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0385","first-page":"1466","article-title":"STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer","volume":"11","author":"Wang","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0390","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","article-title":"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK","volume":"113","author":"Okawa","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0395","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0400","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/10428190801910912","article-title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways","volume":"49","author":"Rizzatti","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0405","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0410","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1073\/pnas.0807611106","article-title":"ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells","volume":"106","author":"Wang","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0415","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.molcel.2010.11.035","article-title":"The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose","volume":"40","author":"Lowman","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0420","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","article-title":"Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy","volume":"16","author":"Wright","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0425","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0430","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","article-title":"Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0435","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0440","first-page":"1661","article-title":"The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405\u2014a Phase II study of VcR-CVAD with maintenance rituximab for MCL","volume":"114","author":"Kahl","year":"2009","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0445","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8022","article-title":"Bortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenance versus observation in previously untreated mantle cell lymphoma (MCL)","volume":"29","author":"Grant","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0450","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0455","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0460","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0465","first-page":"2657","article-title":"Non-proteasomal targets of proteasome inhibitors bortezomib and carfilzomib","volume":"112","author":"Arastu-Kapur","year":"2008","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0470","first-page":"985","article-title":"Results of PX-171-003-A1, an open-label, single-arm Phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"diCapua Siegel","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0475","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0480","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0485","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm048995+","article-title":"Structure\u2013activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor","volume":"48","author":"Macherla","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0490","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0495","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0500","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin\u2013proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0505","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1158\/1078-0432.CCR-09-0343","article-title":"Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer","volume":"15","author":"Soucy","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0510","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1158\/0008-5472.CAN-10-2062","article-title":"NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells","volume":"70","author":"Lin","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0515","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0520","first-page":"2801","article-title":"Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and\/or refractory multiple myeloma or lymphoma","volume":"116","author":"Shah","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0525","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ng.471","article-title":"Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts","volume":"41","author":"Doi","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0530","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nbt.1533","article-title":"Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells","volume":"27","author":"Ball","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0535","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0540","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0545","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","article-title":"Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma","volume":"26","author":"Pal","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0550","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1128\/MCB.23.21.7475-7487.2003","article-title":"mSin3A\/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad","volume":"23","author":"Pal","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0555","series-title":"Mantle cell lymphoma consortium meeting proceedings","article-title":"Developing novel drugs to target protein arginine methyltransferase enzyme 5 (PRMT5) overexpression in mantle cell lymphoma","author":"Baiocchi","year":"2011"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0560","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0565","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CCO.0b013e32833d5954","article-title":"Histone deacetylase inhibitors in lymphoma","volume":"22","author":"Copeland","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0570","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0575","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","article-title":"Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma","volume":"101","author":"Watanabe","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0580","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0585","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"80","author":"Heider","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0590","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0595","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-09-0988","article-title":"Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells","volume":"9","author":"Rao","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0600","first-page":"2856","article-title":"Treatment with histone deacetylase 6-specific inhibitor WT-161 disrupts hsp90 function abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib","volume":"116","author":"Rao","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0605","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0610","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2009.68","article-title":"I-SPY 2 an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy","volume":"86","author":"Barker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0615","first-page":"964","article-title":"The Btk inhibitor, PCI-32765 induces durable responses with minimal toxicity in patients with relapsed\/refractory B-cell malignancies: results from a Phase I study","volume":"116","author":"Fowler","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0620","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0625","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0630","first-page":"2830","article-title":"Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"116","author":"Younes","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts.)"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0635","first-page":"1777","article-title":"Clinical safety and activity in a Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"116","author":"Kahl","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0640","first-page":"657","volume":"116","author":"Andreeff","year":"2010","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.semcancer.2011.09.008_bib0645","first-page":"985","article-title":"Results of PX-171-003-A1, an open-label, single-arm, Phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"diCapua Siegel","year":"2010","journal-title":"ASH Annu Meeting Abstr"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X11000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X11000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T22:57:37Z","timestamp":1712876257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X11000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1044579X11000575"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2011.09.008","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}